Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review

Authors: SP Balasubramanian, IAF Azmy, SE Higham, AG Wilson, SS Cross, A Cox, NJ Brown, MW Reed

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Interleukins and cytokines play an important role in the pathogenesis of many solid cancers. Several single nucleotide polymorphisms (SNPs) identified in cytokine genes are thought to influence the expression or function of these proteins and many have been evaluated for their role in inflammatory disease and cancer predisposition. The aim of this study was to evaluate any role of specific SNPs in the interleukin genes IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 in predisposition to breast cancer susceptibility and severity.

Methods

Candidate single nucleotide polymorphisms (SNPs) in key cytokine genes were genotyped in breast cancer patients and in appropriate healthy volunteers who were similar in age, race and sex. Genotyping was performed using a high throughput allelic discrimination method. Data on clinico-pathological details and survival were collected. A systematic review of Medline English literature was done to retrieve previous studies of these polymorphisms in breast cancer.

Results

None of the polymorphisms studied showed any overall predisposition to breast cancer susceptibility, severity or to time to death or occurrence of distant metastases. The results of the systematic review are summarised.

Conclusion

Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.
Appendix
Available only for authorised users
Literature
1.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004, 202: 275-293. 10.1111/j.0105-2896.2004.00199.x.CrossRefPubMed
2.
de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, Oosterwijk JC, Kleibeuker JH, Schaapveld M, de Vries EG: Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002, 39 (4): 225-242. 10.1136/jmg.39.4.225.CrossRefPubMedPubMedCentral
3.
El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JFJ, Chow WH: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003, 124 (5): 1193-1201. 10.1016/S0016-5085(03)00157-4.CrossRefPubMed
4.
Lu W, Pan K, Zhang L, Lin D, Miao X, You W: Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population. Carcinogenesis. 2005, 26 (3): 631-636. 10.1093/carcin/bgh349.CrossRefPubMed
5.
Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, Greco E, Gallo N, Rugge M, Di Mario F, Plebani M: Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine. 2005, 29 (4): 141-152. 10.1016/j.cyto.2004.10.013.CrossRefPubMed
6.
Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, Yu MC: Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer. 2005, 103 (4): 740-748. 10.1002/cncr.20842.CrossRefPubMed
7.
Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM, Donaldson PT: Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003, 34 (1): 19-26. 10.1385/IJGC:34:1:19.CrossRefPubMed
8.
Campa D, Hung RJ, Mates D, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Bencko V, Foretova L, Janout V, Boffetta P, Brennan P, Canzian F: Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2005, 14 (2): 538-539. 10.1158/1055-9965.EPI-04-0513.CrossRefPubMed
9.
Burmester JK, Suarez BK, Lin JH, Jin CH, Miller RD, Zhang KQ, Salzman SA, Reding DJ, Catalona WJ: Analysis of candidate genes for prostate cancer. Hum Hered. 2004, 57 (4): 172-178. 10.1159/000081443.CrossRefPubMed
10.
Hefler LA, Ludwig E, Lebrecht A, Zeillinger R, Tong-Cacsire D, Koelbl H, Leodolter S, Tempfer CB: Polymorphisms of the interleukin-1 gene cluster and ovarian cancer. J Soc Gynecol Investig. 2002, 9 (6): 386-390. 10.1016/S1071-5576(02)00177-6.CrossRefPubMed
11.
Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, Kreutzer DL: The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol. 2003, 23 (2): 269-284.PubMed
12.
Gooch JL, Lee AV, Yee D: Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. 1998, 58 (18): 4199-4205.PubMed
13.
Obiri NI, Siegel JP, Varricchio F, Puri RK: Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol. 1994, 95 (1): 148-155.CrossRefPubMedPubMedCentral
14.
Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY: Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002, 2 (4): 311-315.CrossRefPubMed
15.
Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003, 103 (5): 642-646. 10.1002/ijc.10833.CrossRefPubMed
16.
Venetsanakos E, Beckman I, Bradley J, Skinner JM: High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1997, 75 (12): 1826-1830.CrossRefPubMedPubMedCentral
17.
Kundu N, Beaty TL, Jackson MJ, Fulton AM: Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst. 1996, 88 (8): 536-541.CrossRefPubMed
18.
Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, Nakshatri H: Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol. 2003, 163 (6): 2531-2541.CrossRefPubMedPubMedCentral
19.
Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desai SB, Atkin SL: Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. Int J Oncol. 1999, 15 (6): 1251-1254.PubMed
20.
Suswam EA, Nabors LB, Huang Y, Yang X, King PH: IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer. 2005, 113 (6): 911-919. 10.1002/ijc.20675.CrossRefPubMed
21.
Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP: Inhibition of angiogenesis by interleukin 4. J Exp Med. 1998, 188 (6): 1039-1046. 10.1084/jem.188.6.1039.CrossRefPubMedPubMedCentral
22.
van den Velden PA, Reitsma PH: Amino acid dimorphism in IL1A is detectable by PCR amplification. Hum Mol Genet. 1993, 2 (10): 1753-CrossRefPubMed
23.
Kawaguchi Y, Tochimoto A, Ichikawa N, Harigai M, Hara M, Kotake S, Kitamura Y, Kamatani N: Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum. 2003, 48 (1): 186-192. 10.1002/art.10736.CrossRefPubMed
24.
Berger P, McConnell JP, Nunn M, Kornman KS, Sorrell J, Stephenson K, Duff GW: C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine. 2002, 17 (4): 171-174. 10.1006/cyto.2001.0974.CrossRefPubMed
25.
Li QY, Zhao HS, Meng HX, Zhang L, Xu L, Chen ZB, Shi D, Feng XH, Zhu XL: Association analysis between interleukin-1 family polymorphisms and generalized aggressive periodontitis in a Chinese population. J Periodontol. 2004, 75 (12): 1627-1635. 10.1902/jop.2004.75.12.1627.CrossRefPubMed
26.
Eklund C, Jahan F, Pessi T, Lehtimaki T, Hurme M: Interleukin 1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur Cytokine Netw. 2003, 14 (3): 168-171.PubMed
27.
Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J: A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest. 1992, 22 (6): 396-402.CrossRefPubMed
28.
Dziedzic T, Slowik A, Pera J, Szczudlik A: Interleukin 1 Beta Polymorphism (-511) and Risk of Stroke due to Small Vessel Disease. Cerebrovasc Dis. 2005, 20 (5): 299-303. 10.1159/000087928.CrossRefPubMed
29.
Perri F, Piepoli A, Bonvicini C, Gentile A, Quitadamo M, Di Candia M, Cotugno R, Cattaneo F, Zagari MR, Ricciardiello L, Gennarelli M, Bazzoli F, Ranzani GN, Andriulli A: Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine. 2005, 30 (5): 293-302. 10.1016/j.cyto.2005.01.011.CrossRefPubMed
30.
Zhang WH, Wang XL, Zhou J, An LZ, Xie XD: Association of interleukin-1B (IL-1B) gene polymorphisms with risk of gastric cancer in Chinese population. Cytokine. 2005, 30 (6): 378-381. 10.1016/j.cyto.2005.02.002.CrossRefPubMed
31.
Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, Canestrari E, Catalano V, Humar B, Ficarelli R, Bearzi I, Cascinu S, Naldi N, Testa E, Magnani M: Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Ann Oncol. 2005, 16 (6): 887-892. 10.1093/annonc/mdi184.CrossRefPubMed
32.
Hurme M, Santtila S: IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol. 1998, 28 (8): 2598-2602. 10.1002/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.0.CO;2-K.CrossRefPubMed
33.
Santtila S, Savinainen K, Hurme M: Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol. 1998, 47 (3): 195-198. 10.1046/j.1365-3083.1998.00300.x.CrossRefPubMed
34.
Hu Z, Shao M, Chen Y, Zhou J, Qian J, Xu L, Ma H, Wang X, Xu Y, Lu D, Shen H: Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer. Cancer Lett. 2005
35.
Sehouli J, Mustea A, Koensgen D, Lichtenegger W: Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003, 12 (11 Pt 1): 1205-1208.PubMed
36.
Mustea A, Sehouli J, Konsgen D, Stengel D, Sofroni D, Lichtenegger W: Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. Anticancer Res. 2003, 23 (2A): 1099-1102.PubMed
37.
Gough MD, Ackroyd R, Majeed AW, Bird NC: Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?. Am J Gastroenterol. 2005, 100 (5): 1012-1018. 10.1111/j.1572-0241.2005.40904.x.CrossRefPubMed
38.
Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA: The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 1997, 337 (24): 1720-1725. 10.1056/NEJM199712113372403.CrossRefPubMed
39.
Aithal GP, Day CP, Leathart J, Daly AK, Hudson M: Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes Immun. 2001, 2 (1): 44-47. 10.1038/sj.gene.6363730.CrossRefPubMed
40.
Cui T, Wang L, Wu J, Hu L, Xie J: Polymorphisms of IL-4, IL-4R alpha, and AICDA genes in adult allergic asthma. J Huazhong Univ Sci Technolog Med Sci. 2003, 23 (2): 134-137.CrossRefPubMed
41.
Nakamura E, Megumi Y, Kobayashi T, Kamoto T, Ishitoya S, Terachi T, Tachibana M, Matsushiro H, Habuchi T, Kakehi Y, Ogawa O: Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res. 2002, 8 (8): 2620-2625.PubMed
42.
Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998, 102 (7): 1369-1376.CrossRefPubMedPubMedCentral
43.
Ogilvie EM, Fife MS, Thompson SD, Twine N, Tsoras M, Moroldo M, Fisher SA, Lewis CM, Prieur AM, Glass DN, Woo P: The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003, 48 (11): 3202-3206. 10.1002/art.11300.CrossRefPubMed
44.
Georges JL, Loukaci V, Poirier O, Evans A, Luc G, Arveiler D, Ruidavets JB, Cambien F, Tiret L: Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Mol Med. 2001, 79 (5-6): 300-305. 10.1007/s001090100209.CrossRefPubMed
45.
Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ: The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001, 22 (24): 2243-2252. 10.1053/euhj.2001.2678.CrossRefPubMed
46.
Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X: Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005, 23 (24): 5746-5756. 10.1200/JCO.2005.01.598.CrossRefPubMed
47.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F: Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003, 63 (13): 3560-3566.PubMed
48.
Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ: An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood. 2000, 96 (7): 2562-2567.PubMed
49.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997, 24 (1): 1-8.CrossRefPubMed
50.
Fernandez L, Martinez A, Mendoza JL, Urcelay E, Fernandez-Arquero M, Garcia-Paredes J, Diaz-Rubio M, de la Concha EG: Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis. 2005, 11 (8): 739-743. 10.1097/01.MIB.0000173457.64868.20.CrossRefPubMed
51.
Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH, Kim YJ, Lee HS: Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet. 2003, 12 (8): 901-906. 10.1093/hmg/ddg104.CrossRefPubMed
52.
Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C: Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res. 2005, 15 (1): 53-60. 10.1097/00008390-200502000-00009.CrossRefPubMed
53.
Rafii S, O'Regan P, Xinarianos G, Azmy I, Stephenson T, Reed M, Meuth M, Thacker J, Cox A: A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet. 2002, 11 (12): 1433-1438. 10.1093/hmg/11.12.1433.CrossRefPubMed
54.
Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, Brown NJ, Reed MW: Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res. 2004, 6 (4): R395-400. 10.1186/bcr802.CrossRefPubMedPubMedCentral
55.
di Giovine F. S. CNJCACAGSJACADGW: Detection and population analysis of IL-1 and TNF gene polymorphisms. Cytokine Molecular Biology - A practical approach. Edited by: Balkwill F. 2000, Oxford , Oxford University Press, 21-46.
56.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21 (2): 263-265. 10.1093/bioinformatics/bth457.CrossRefPubMed
57.
Smith KC, Bateman AC, Fussell HM, Howell WM: Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet. 2004, 31 (4): 167-173. 10.1111/j.1365-2370.2004.00462.x.CrossRefPubMed
58.
Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H, Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R: Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res. 2005, 11 (16): 5718-5721. 10.1158/1078-0432.CCR-05-0001.CrossRefPubMed
59.
Skerrett DL, Moore EM, Bernstein DS, Vahdat L: Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest. 2005, 23 (3): 208-214.CrossRefPubMed
60.
Saha A, Bairwa NK, Ranjan A, Gupta V, Bamezai R: Two novel somatic mutations in the human interleukin 6 promoter region in a patient with sporadic breast cancer. Eur J Immunogenet. 2003, 30 (6): 397-400. 10.1111/j.1365-2370.2003.00423.x.CrossRefPubMed
61.
DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B: Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003, 63 (22): 8051-8056.PubMed
62.
Iacopetta B, Grieu F, Joseph D: The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer. 2004, 90 (2): 419-422. 10.1038/sj.bjc.6601545.CrossRefPubMedPubMedCentral
63.
Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A: Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem. 2003, 49 (10): 1664-1667. 10.1373/49.10.1664.CrossRefPubMed
64.
Wu JM, Bensen-Kennedy D, Miura Y, Thoburn CJ, Armstrong D, Vogelsang GB, Hess AD: The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant. 2005, 11 (6): 455-464. 10.1016/j.bbmt.2005.03.008.CrossRefPubMed
65.
Nozaki S, Sledge GWJ, Nakshatri H: Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun. 2000, 275 (1): 60-62. 10.1006/bbrc.2000.3241.CrossRefPubMed
66.
Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G, Kreutzer DL: Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000, 18 (4): 293-302.CrossRefPubMed
67.
Ito LS, Iwata H, Hamajima N, Saito T, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Inoue M, Hirose K, Tajima K: Significant reduction in breast cancer risk for Japanese women with interleukin 1B -31 CT/TT relative to CC genotype. Jpn J Clin Oncol. 2002, 32 (10): 398-402. 10.1093/jjco/hyf081.CrossRefPubMed
68.
Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, Goldberg ID, Rosen EM: Expression of interleukin-1beta in human breast carcinoma. Cancer. 1997, 80 (3): 421-434. 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z.CrossRefPubMed
69.
Honma S, Shimodaira K, Shimizu Y, Tsuchiya N, Saito H, Yanaihara T, Okai T: The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J. 2002, 49 (3): 371-377.CrossRefPubMed
70.
Nicklin MJ, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K: A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics. 2002, 79 (5): 718-725. 10.1006/geno.2002.6751.CrossRefPubMed
71.
Lindmark F, Zheng SL, Wiklund F, Balter KA, Sun J, Chang B, Hedelin M, Clark J, Johansson JE, Meyers DA, Adami HO, Isaacs W, Gronberg H, Xu J: Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer. 2005, 93 (4): 493-497. 10.1038/sj.bjc.6602729.CrossRefPubMedPubMedCentral
72.
Kawakami K, Kawakami M, Husain SR, Puri RK: Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor alpha chain. Clin Cancer Res. 2003, 9 (5): 1826-1836.PubMed
73.
Bugawan TL, Mirel DB, Valdes AM, Panelo A, Pozzilli P, Erlich HA: Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos. Am J Hum Genet. 2003, 72 (6): 1505-1514. 10.1086/375655.CrossRefPubMedPubMedCentral
74.
Berger FG: The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat. 2004, 88 (3): 281-285. 10.1007/s10549-004-0726-0.CrossRefPubMed
75.
Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000, 275 (24): 18138-18144. 10.1074/jbc.M000379200.CrossRefPubMed
76.
Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S, D'Ambrosio FP: Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett. 1999, 68 (2-3): 355-358. 10.1016/S0165-2478(99)00067-X.CrossRefPubMed
77.
Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003, 48: 82-84.PubMed
78.
Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F: Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol. 2003, 120 (1): 99-103. 10.1046/j.1523-1747.2003.12016.x.CrossRefPubMed
79.
Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Koppel H, Wascher TC, Paulweber B, Samonigg H: Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2005, 90 (2): 113-115. 10.1007/s10549-004-3607-7.CrossRefPubMed
Metadata
Title
Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review
Authors
SP Balasubramanian
IAF Azmy
SE Higham
AG Wilson
SS Cross
A Cox
NJ Brown
MW Reed
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-188

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Cross-platform expression profiling demonstrates that SV40 small tumor antigen activates Notch, Hedgehog, and Wnt signaling in human cells

Research article

The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer

Research article

CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways

Research article

Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China

Research article

Eukaryotic Initiation Factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer

Research article

Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits